Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers

Schizophrenia Research

Volumn 174, Issue 1-3, 2016, Pages 99-105

  Handley, Rowena ^a,b   Mondelli, Valeria ^a,c   Zelaya, Fernando ^a   Marques, Tiago ^a   Taylor, Heather ^a   Reinders, Antje A T S ^a   Chaddock, Christopher ^a   McQueen, Grant ^a   Hubbard, Kathryn ^a   Papadopoulos, Andrew ^a   Williams, Steve ^a,c   McGuire, Philip ^a   Pariante, Carmine ^a,c   Dazzan, Paola ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotic; Cerebral blood flow; Cortisol; Dopamine; Hippocampus; Inflammation

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; HYDROCORTISONE; INTERLEUKIN 6; NEUROLEPTIC AGENT; PLACEBO; IL6 PROTEIN, HUMAN; SPIN LABEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; DRUG EFFICACY; DRUG RESPONSE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; MIDDLE AGED; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADOLESCENT; BLOOD; BRAIN CIRCULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REST; SALIVA; VASCULARIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CEREBROVASCULAR CIRCULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALOPERIDOL; HIPPOCAMPUS; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; REST; SALIVA; SPIN LABELS; YOUNG ADULT;

EID: 84964589700     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.03.039     Document Type: Article

References (53)

1. Aguilar-Valles A., Jung S., Poole S., Flores C., Luheshi G.N. Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology 2012, 37:956-969.
2. Aiello G., Horowitz M., Hepgul N., Pariante C.M., Mondelli V. Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with "at risk" mental state. Psychoneuroendocrinology 2012, 37:1600-1613.
3. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
4. Basu S., Dasgupta P.S. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 2000, 102:113-124.
5. Baumeister D., Ciufolini S., Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?. Psychopharmacology 2016, 233:1575-1589.
6. Beck G., Brinkkoetter P., Hanusch C., Schulte J., van Ackern K., van der Woude F.J., Yard B.A. Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit. Care 2004, 8:485-491.
7. Bonne O., Gilboa A., Louzoun Y., Brandes D., Yona I., Lester H., Barkai G., Freedman N., Chisin R., Shalev A.Y. Resting regional cerebral perfusion in recent posttraumatic stress disorder. Biol. Psychiatry 2003, 54:1077-1086.
8. Borges S., Gayer-Anderson C., Mondelli V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology 2013, 38:603-611.
9. Borowsky B., Kuhn C.M. D1 and D2 dopamine receptors stimulate hypothalamo-pituitary-adrenal activity in rats. Neuropharmacology 1992, 31:671-678.
10. Bowman G., Dixit S., Bonneau R.H., Chinchilli V.M., Cockroft K.M. Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model. Neurosurgery 2004, 54:719-725. (discussion 725-716).
11. Cohrs S., Roher C., Jordan W., Meier A., Huether G., Wuttke W., Ruther E., Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 2006, 185:11-18.
12. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Mallett R.M., Jones P.B., Leff J., Murray R.M. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005, 30:765-774.
13. de Leon M.J., McRae T., Rusinek H., Convit A., De Santi S., Tarshish C., Golomb J., Volkow N., Daisley K., Orentreich N., McEwen B. Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer's disease. J. Clin. Endocrinol. Metab. 1997, 82:3251-3259.
14. de Quervain D.J., Henke K., Aerni A., Treyer V., McGaugh J.L., Berthold T., Nitsch R.M., Buck A., Roozendaal B., Hock C. Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. Eur. J. Neurosci. 2003, 17:1296-1302.
15. Eickhoff S.B., Stephan K.E., Mohlberg H., Grefkes C., Fink G.R., Amunts K., Zilles K. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. NeuroImage 2005, 25:1325-1335.
16. Endo Y., Nishimura J., Kimura F. Adrenalectomy increases local cerebral blood flow in the rat hippocampus. Pflugers Arch. - Eur. J. Physiol. 1994, 426:183-188.
17. Endo Y., Nishimura J.I., Kobayashi S., Kimura F. Long-term glucocorticoid treatments decrease local cerebral blood flow in the rat hippocampus, in association with histological damage. Neuroscience 1997, 79:745-752.
18. Endo Y., Nishimura J.I., Kobayashi S., Kimura F. Chronic stress exposure influences local cerebral blood flow in the rat hippocampus. Neuroscience 1999, 93:551-555.
19. Foreman M.M., Fuller R.W., Hynes M.D., Gidda J.S., Nichols C.L., Schaus J.M., Kornfeld E.C., Clemens J.A. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist. J. Pharmacol. Exp. Ther. 1989, 250:227-235.
20. Goozee R., Handley R., Kempton M.J., Dazzan P. A systematic review and meta-analysis of the effects of antipsychotic medications on regional cerebral blood flow (rCBF) in schizophrenia: association with response to treatment. Neurosci. Biobehav. Rev. 2014, 43:118-136.
21. Goozee R., Reinders A.A., Handley R., Marques T., Taylor H., O'Daly O., McQueen G., Hubbard K., Mondelli V., Pariante C., Dazzan P. Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: a functional MRI study. Schizophr. Res. 2016, 173:174-181.
22. Handley R., Zelaya F.O., Reinders A.A., Marques T.R., Mehta M.A., O'Gorman R., Alsop D.C., Taylor H., Johnston A., Williams S., McGuire P., Pariante C.M., Kapur S., Dazzan P. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Hum. Brain Mapp. 2013, 34:272-282.
23. Hennig J., Rzepka U., Mai B., Netter P. Suppression of HPA-axis activity by haloperidol after experimentally induced heat stress. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1995, 19:603-614.
24. Himmerich H., Schonherr J., Fulda S., Sheldrick A.J., Bauer K., Sack U. Impact of antipsychotics on cytokine production in-vitro. J. Psychiatr. Res. 2011, 45:1358-1365.
25. Hodkinson D.J., O'Daly O., Zunszain P.A., Pariante C.M., Lazurenko V., Zelaya F.O., Howard M.A., Williams S.C. Circadian and homeostatic modulation of functional connectivity and regional cerebral blood flow in humans under normal entrained conditions. J. Cereb. Blood Flow Metab. 2014, 34:1493-1499.
26. Itoh H., Katagiri F., Ikawa K., Takeyama M. Effects of domperidone on human plasma levels of motilin, somatostatin, gastrin, adrenocorticotropic hormone and cortisol. Biol. Pharm. Bull. 2005, 28:1752-1756.
27. Jakovljevic M., Pivac N., Mihaljevic-Peles A., Mustapic M., Relja M., Ljubicic D., Marcinko D., Muck-Seler D. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:399-402.
28. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29:141-152.
29. Maher C.O., Anderson R.E., Martin H.S., McClelland R.L., Meyer F.B. Interleukin-1beta and adverse effects on cerebral blood flow during long-term global hypoperfusion. J. Neurosurg. 2003, 99:907-912.
30. Mamo D., Graff A., Mizrahi R., Shammi C.M., Romeyer F., Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatr. 2007, 164:1411-1417.
31. Marsland A.L., Gianaros P.J., Abramowitch S.M., Manuck S.B., Hariri A.R. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol. Psychiatry 2008, 64:484-490.
32. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989, 99:S18-S27. (Suppl.).
33. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
34. Mondelli V., Dazzan P., Hepgul N., Di Forti M., Aas M., D'Albenzio A., Di Nicola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
35. Mondelli V., Pariante C.M., Navari S., Aas M., D'Albenzio A., Di Forti M., Handley R., Hepgul N., Marques T.R., Taylor H., Papadopoulos A.S., Aitchison K.J., Murray R.M., Dazzan P. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr. Res. 2010, 119:75-78.
36. Mondelli V., Cattaneo A., Belvederi Murri M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72:1677-1684.
37. Mondelli V., Ciufolini S., Belvederi Murri M., Bonaccorso S., Di Forti M., Giordano A., Marques T.R., Zunszain P.A., Morgan C., Murray R.M., Pariante C.M., Dazzan P. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 2015, 41:1162-1170.
38. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39:1763-1777.
39. Oswald L.M., Wong D.F., McCaul M., Zhou Y., Kuwabara H., Choi L., Brasic J., Wand G.S. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005, 30:821-832.
40. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., Popovic S., Miljic N., Djurovic M., Jasovic-Gasic M., Dieguez C., Casanueva F.F. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
41. Pruessner J.C., Kirschbaum C., Meinlschmid G., Hellhammer D.H. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28:916-931.
42. Pruessner J.C., Dedovic K., Khalili-Mahani N., Engert V., Pruessner M., Buss C., Renwick R., Dagher A., Meaney M.J., Lupien S. Deactivation of the limbic system during acute psychosocial stress: evidence from positron emission tomography and functional magnetic resonance imaging studies. Biol. Psychiatry 2008, 63:234-240.
43. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
44. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. Am. J. Psychiatr. 2010, 167:1178-1193.
45. Tanaka K., Morinobu S., Ichimura M., Asakawa A., Inui A., Hosoda H., Kangawa K., Yamawaki S. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32:1527-1532.
46. Tarkowski E., Rosengren L., Blomstrand C., Wikkelso C., Jensen C., Ekholm S., Tarkowski A. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995, 26:1393-1398.
47. Tourjman V., Kouassi E., Koue M.E., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151:43-47.
48. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997, 104:667-685.
49. Wand G.S., Oswald L.M., McCaul M.E., Wong D.F., Johnson E., Zhou Y., Kuwabara H., Kumar A. Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress. Neuropsychopharmacology 2007, 32:2310-2320.
50. Wetzel H., Wiesner J., Hiemke C., Benkert O. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J. Psychiatr. Res. 1994, 28:461-473.
51. Zajkowska Z., Mondelli V. First-episode psychosis: an inflammatory state?. Neuroimmunomodulation 2014, 21:102-108.
52. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.
53. Zunszain P.A., Anacker C., Cattaneo A., Carvalho L.A., Pariante C.M. Glucocorticoids, cytokines and brain abnormalities in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:722-729.